Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors

NCT02100007 is registered in ClinicalTrials.gov with MEI Pharma, Inc. as lead sponsor.

NCT NCT02100007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02100007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors
Lead sponsor
MEI Pharma, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2014
Completion date
April 30, 2016
Enrollment
46 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors